Start date: 01 March 2023
End date: 28 February 2029
HT-ADVANCE we aim to revolutionise personalised management of arterial hypertension (HT) by using multi-omics (MOMICS) stratification biomarkers as companion diagnostics for the prescription of existing drugs.
High blood pressure or hypertension is a condition that affects the body’s arteries and increases the risk of heart disease. Understanding the underlying cause of hypertension as well as identifying endocrine hypertension are central for therapy. The EU-funded HT-ADVANCE project aims to validate multi-component biomarkers in clinical trials that can help stratify and improve treatment of patients with hypertension. The biomarkers integrate genetic, genomic and metabolomic features that relate to the form of hypertension. Long-term, the implementation of these biomarkers in routine clinical practice is expected to reduce cardio-metabolic complications and improve hypertension management.
Scientific coordinator of the project: Maria-Christina Zennaro